Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.

Murray NP, Reyes E, Tapia P, Badinez L, Orellana N, Fuentealba C, Olivares R, DueƱas R.

Arch Esp Urol. 2013 May;66(4):335-41. English, Spanish.

PMID:
23676536
2.

Prostate biopsy: who, how and when. An update.

Djavan B, Milani S, Remzi M.

Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100. Review.

PMID:
15780165
3.

Incidental carcinoma of the prostate.

van Andel G, Vleeming R, Kurth K, de Reijke TM.

Semin Surg Oncol. 1995 Jan-Feb;11(1):36-45. Review.

PMID:
7538693
4.
5.

Diagnosis of prostate cancer.

Pinthus JH, Pacik D, Ramon J.

Recent Results Cancer Res. 2007;175:83-99. Review.

PMID:
17432555
6.

Age-specific reference ranges for PSA in the detection of prostate cancer.

DeAntoni EP.

Oncology (Williston Park). 1997 Apr;11(4):475-82, 485; discussion 485-6, 489. Review.

7.

Overdetection in screening for prostate cancer.

Hugosson J, Carlsson S.

Curr Opin Urol. 2014 May;24(3):256-63. doi: 10.1097/MOU.0000000000000054. Review.

PMID:
24670870
8.

The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.

Saad F, Pantel K.

Future Oncol. 2012 Mar;8(3):321-31. doi: 10.2217/fon.12.3. Review.

PMID:
22409467
9.

Prostate biopsy in the diagnosis of prostate cancer: current trends and techniques.

Lowe FC, Nagler EA.

Drugs Today (Barc). 2005 Mar;41(3):179-91. Review.

PMID:
15883615
10.

The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer.

Abdollah F, Dalela D, Haffner MC, Culig Z, Schalken J.

Eur Urol Focus. 2015 Sep;1(2):99-108. doi: 10.1016/j.euf.2015.08.001. Epub 2015 Aug 28. Review.

PMID:
28723439
11.

The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology.

Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM.

Urol Oncol. 2004 Jul-Aug;22(4):337-43. Review.

PMID:
15283893
12.

Biomarkers in prostate cancer: new era and prospective.

Mohammed AA.

Med Oncol. 2014 Aug;31(8):140. doi: 10.1007/s12032-014-0140-3. Epub 2014 Jul 22. Review.

PMID:
25048724
13.

Biomarkers for the diagnosis of new and recurrent prostate cancer.

Sardana G, Diamandis EP.

Biomark Med. 2012 Oct;6(5):587-96. doi: 10.2217/bmm.12.72. Review.

PMID:
23075237
14.

Mass screening program for prostatic cancer in Japan.

Watanabe H.

Int J Clin Oncol. 2001 Apr;6(2):66-73. Review.

PMID:
11706752
15.

Progress and problems in screening for carcinoma of the prostate.

Chodak GW, Schoenberg HW.

World J Surg. 1989 Jan-Feb;13(1):60-4. Review.

PMID:
2658355
16.

Screening for prostate cancer.

Gambert SR.

Int Urol Nephrol. 2001;33(2):249-57. Review.

PMID:
12092637
17.

The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsies.

Wojno K, Hornberger J, Schellhammer P, Dai M, Morgan T.

J Urol. 2015 Apr;193(4):1170-7. doi: 10.1016/j.juro.2014.11.019. Epub 2014 Nov 14. Review.

PMID:
25463992
18.
19.

[Benign mimics of prostatic adenocarcinoma].

Kovylina MV, Prilepskaia EA, Govorov AV, D'iakov VV, Kolontarev KB, Vasil'ev AO, Sidorenkov AV, Rasner PI, Glotov AV, Pushkar' DIu, Nikitaev VG, Pronichev AN.

Urologiia. 2014 Nov-Dec;(6):51-6. Review. Russian.

PMID:
25799728
20.

Commercialized biomarkers: new horizons in prostate cancer diagnostics.

Murphy L, Prencipe M, Gallagher WM, Watson RW.

Expert Rev Mol Diagn. 2015 Apr;15(4):491-503. doi: 10.1586/14737159.2015.1011622. Epub 2015 Feb 24. Review.

PMID:
25711191

Supplemental Content

Support Center